Who
Shalini Sharp
Director
Company insider
Files Form 4 as: Director, Iambic Therapeutics; Director, Septerna; Director, Organon & Co; Director, BeOne Medicines; Director, Neurocrine Biosciences; Director, Mirati Therapeutics; Director, Sutro Biopharma; Director, Precision BioSciences.
In numbers
- Trades disclosed
- 275
- Buys
- 3
- Sells
- 47
- Bought
- $114K
- Sold
- $18.3M
- Companies
- 12
- Companies where not an officer
- 10
- First trade
- 5 Jan 2007
- Last trade
- 14 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 16 Oct 2026 | IAM Iambic Therapeuticsoption or derivative | SEC FORM 4 Code A | —20,300 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $240K17,857.143 at $13.44 | filing |
| 12 Jun 2026filed 15 Jun 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $240K17,857.14 at $13.44 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —18,980 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —18,980 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,567 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,567 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —1,659 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,659 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,659 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —1,659 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,623 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $240K23,904.38 at $10.04 | filing |
| 22 May 2025filed 22 May 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,435 at $0.00 | filing |
| 22 May 2025filed 22 May 2025 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —1,435 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,659 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,305 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,750 at $0.00 | filing |
News
Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RARE · themarketsdaily.com · 15 Oct 2026Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashRARE · tickerreport.com · 14 Oct 2026ImageneBio (NASDAQ:IMA) versus Agenus (NASDAQ:AGEN) Financial SurveyAGEN · dailypolitical.com · 11 Oct 2026Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Shalini Sharp; 4 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.